286 related articles for article (PubMed ID: 27544930)
1. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
[TBL] [Abstract][Full Text] [Related]
2. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
3. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
5. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
[TBL] [Abstract][Full Text] [Related]
6. Results of PONDx, a prospective multicenter study of the Oncotype DX
Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
8. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
9. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
10. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
11. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
12. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
[TBL] [Abstract][Full Text] [Related]
14. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
15. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
16. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
[TBL] [Abstract][Full Text] [Related]
17. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
Mao Y; Chen XS; Liang Y; Wu JY; Huang O; Zong Y; Fang Q; He JR; Zhu L; Chen WG; Li YF; Lin L; Fei XC; Shen KW
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):502-508. PubMed ID: 28728295
[No Abstract] [Full Text] [Related]
18. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
[TBL] [Abstract][Full Text] [Related]
20. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
